|
1
|
Aktas G: A comprehensive review on
rational and effective treatment strategies against an invisible
enemy; SARS Cov-2 infection. Exp Biomed Res. 3:293–311. 2020.
|
|
2
|
Wu Z and McGoogan JM: Characteristics of
and important lessons from the coronavirus disease 2019 (COVID-19)
outbreak in China: Summary of a report of 72 314 cases from the
Chinese center for disease control and prevention. JAMA.
323:1239–1242. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Aktas G: Hematological predictors of novel
coronavirus infection. Rev Assoc Med Bras (1992). 67 (Suppl
1):S1–S2. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Khalid A, Ali Jaffar M, Khan T, Abbas Lail
R, Ali S, Aktas G, Waris A, Javaid A, Ijaz N and Muhammad N:
Hematological and biochemical parameters as diagnostic and
prognostic markers in SARS-COV-2 infected patients of Pakistan: A
retrospective comparative analysis. Hematology. 26:529–542.
2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chen B, Tian EK, He B, Tian L, Han R, Wang
S, Xiang Q, Zhang S, El Arnaout T and Cheng W: Overview of lethal
human coronaviruses. Signal Transduct Target Ther.
5(89)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Riedel S: Edward Jenner and the history of
smallpox and vaccination. Proc (Bayl Univ Med Cent). 18:21–25.
2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Plotkin S: History of vaccination. Proc
Natl Acad Sci USA. 111:12283–12287. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Polack FP, Thomas SJ, Kitchin N, Absalon
J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED,
Zerbini C, et al: Safety and efficacy of the BNT162b2 mRNA Covid-19
vaccine. N Engl J Med. 383:2603–2615. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Vanaparthy R, Mohan G, Vasireddy D and
Atluri P: Review of COVID-19 viral vector-based vaccines and
COVID-19 variants. Infez Med. 29:328–338. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dadras O, Mehraeen E, Karimi A, Tantuoyir
MM, Afzalian A, Nazarian N, Mojdeganlou H, Mirzapour P, Shamsabadi
A, Dashti M, et al: Safety and adverse events related to
inactivated COVID-19 vaccines and novavax; a systematic review.
Arch Acad Emerg Med. 10(e54)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gorman MJ, Patel N, Guebre-Xabier M, Zhu
AL, Atyeo C, Pullen KM, Loos C, Goez-Gazi Y, Carrion R Jr, Tian JH,
et al: Fab and Fc contribute to maximal protection against
SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M
vaccination. Cell Rep Med. 2(100405)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang J, He Q, An C, Mao Q, Gao F, Bian L,
Wu X, Wang Q, Liu P, Song L, et al: Boosting with heterologous
vaccines effectively improves protective immune responses of the
inactivated SARS-CoV-2 vaccine. Emerg Microbes Infect.
10:1598–1608. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Song X, Hu W, Yu H, Zhao L and Zhao Y,
Zhao X, Xue HH and Zhao Y: Little to no expression of
angiotensin-converting enzyme-2 on most human peripheral blood
immune cells but highly expressed on tissue macrophages. Cytometry
A. 103:136–145. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Khalis M, Boucham M, Luo A, Marfak A, Saad
S, Mariama Aboubacar C, Ait El Haj S, Jallal M, Aazi FZ, Charaka H
and Nejjari C: COVID-19 vaccination acceptance among health science
students in morocco: A cross-sectional study. Vaccines (Basel).
9(1451)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Maci SM: The (Re) creation of
self-identity in times of crises: The case of AstraZeneca
press-releases. Elephant Castle. 96–110. 2024.
|
|
16
|
Anvari E, Ghamar Talepoor A, Eshkevar
Vakili M, Karimi N, Ataollahi M, Najafi G, Kabelitz D, Ahmadi I and
Kalantar K: Comparison of the antibody responses following
vaccination with AstraZeneca and Sinopharm. Iran J Immunol.
19:321–329. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nappi F, Iervolino A and Avtaar Singh SS:
COVID-19 pathogenesis: From molecular pathway to vaccine
administration. Biomedicines. 9(903)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gard L, Fliss MA, Bosma F, Ter Veen D and
Niesters HGM: Validation and verification of the
GeneFinder™ COVID-19 Plus RealAmp kit on the ELITe
InGenius® instrument. J Virol Methods.
300(114378)2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gilda LP, Sheila CV, Hany GF, Giselle FC,
Amalia VA, Beatriz AA, Lismary AD, Ricardo MR, Yahima CQ, Edelgis
CR, et al: Elevated antibody titers in Abdala vaccinees evaluated
by Elecsys® anti-SARS-CoV-2 S highly correlate with
UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral
neutralization assays. J Biomed Biotechnol. 5(154)2022.
|
|
21
|
Ma J, Cheng ZJ, Xue M, Huang H, Li S, Fang
Y, Zeng Y, Lin R, Liang Z, Liang H, et al: Investigation of
antibody levels during three doses of Sinopharm/BBIBP vaccine
inoculation. Front Immunol. 13(913732)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Baden LR, El Sahly HM, Essink B, Kotloff
K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB,
et al: COVE study group: Efficacy and safety of the mRNA-1273
SARS-CoV-2 vaccine. N Engl J Med. 384:403–416. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yan Y, Chang L and Wang L: Laboratory
testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current
status, challenges, and countermeasures. Rev Med Virol.
30(e2106)2020.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Holt SG, Mahmoud S, Ahmed W, Acuna JM, Al
Madani AK, Eltantawy I, Zaher WA, Goodier GJ, Al Kaabi NA and Al
Obaidli AA: An analysis of antibody responses and clinical sequalae
of the Sinopharm HB02 COVID19 vaccine in dialysis patients in the
United Arab Emirates. Nephrology (Carlton). 27:260–268.
2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Halloran ME, Longini IM Jr and Struchiner
CJ: Design and interpretation of vaccine field studies. Epidemiol
Rev. 21:73–88. 1999.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mubarak A, Almutairi S, Al-Dhabbah AD,
Aldabas SY, Bhat R, Alqoufail MM, Abdel-Maksoud MA, Almanaa TN,
Farrag MA and Alturaiki W: Durability of SARS-CoV-2 specific IgG
antibody responses following two doses of match and mixed COVID-19
vaccines regimens in Saudi population. Infect Drug Resist.
15:3791–3800. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Upreti S and Samant M: A review on
immunological responses to SARS-CoV-2 and various COVID-19 vaccine
regimens. Pharm Res. 39:2119–2134. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Martin JE, Louder MK, Holman LA, Gordon
IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M,
et al: A SARS DNA vaccine induces neutralizing antibody and
cellular immune responses in healthy adults in a phase I clinical
trial. Vaccine. 26:6338–6343. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Siegrist CA and Aspinall R: B-cell
responses to vaccination at the extremes of age. Nat Rev Immunol.
9:185–194. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Higgins V, Fabros A and Kulasingam V:
Quantitative measurement of anti-SARS-CoV-2 antibodies: Analytical
and clinical evaluation. J Clin Microbiol. 59:e03149–20.
2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Eyre DW, Lumley SF, Wei J, Cox S, James T,
Justice A, Jesuthasan G, O'Donnell D, Howarth A, Hatch SB, et al:
Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and
Oxford-AstraZeneca vaccines by previous infection status. Clin
Microbiol Infect. 27:1516.e7–1516.e14. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lipsitch M and Kahn R: Interpreting
vaccine efficacy trial results for infection and transmission.
Vaccine. 39:4082–4088. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gustafson CE, Kim C, Weyand CM and Goronzy
JJ: Influence of immune aging on vaccine responses. J Allergy Clin
Immunol. 145:1309–1321. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi
CH and Moulton VR: Aging, immunity, and COVID-19: How age
influences the host immune response to coronavirus infections.
Front Physiol. 11(571416)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Giefing-Kröll C, Berger P, Lepperdinger G
and Grubeck-Loebenstein B: How sex and age affect immune responses,
susceptibility to infections, and response to vaccination. Aging
Cell. 14:309–321. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Farid E, Herrera-Uribe J and Stevenson NJ:
The effect of age, gender and comorbidities upon SARS-CoV-2 spike
antibody induction after two doses of sinopharm vaccine and the
effect of a pfizer/BioNtech booster vaccine. Front Immunol.
13(817597)2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
El-Ghitany EM, Hashish MH, Farag S, Omran
EA, Farghaly AG and Azzam NFAEM: Determinants of the development of
SARS-CoV-2 anti-spike immune-response after vaccination among
healthcare workers in Egypt. Vaccines (Basel).
10(174)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Boshra MS, Hussein RRS, Mohsen M, Elberry
AA, Altyar AE, Tammam M and Sarhan RM: A battle against COVID-19:
Vaccine hesitancy and awareness with a comparative study between
sinopharm and AstraZeneca. Vaccines (Basel). 10(292)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang H, Zhang Y, Huang B, Deng W, Quan Y,
Wang W, Xu W, Zhao Y, Li N, Zhang J, et al: Development of an
inactivated vaccine candidate, BBIBP-CorV, with potent protection
against SARS-CoV-2. Cell. 182:713–721.e9. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Letafati A, Eyvazzadeh N, Gharehkhani A,
Khorshidian A, Chalabiani S, Soufiani EK, Khakpoor N, Shamsodini B,
Beheshti T, Bavili Olyaei RT, et al: Comparison of AstraZeneca and
sinopharm vaccines as boosters in protection against COVID-19
infection. Biologicals. 82(101668)2023.PubMed/NCBI View Article : Google Scholar
|
